Click Here for 5% Off Your First Aladdin Purchase!

PF-06446846 hydrochloride - 99%, high purity , CAS No.1632250-50-0

  • ≥99%
Item Number
P646701
Grouped product items
SKUSizeAvailabilityPrice Qty
P646701-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$75.90
P646701-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$275.90
P646701-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$440.90
P646701-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$715.90
P646701-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,320.90
P646701-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,310.90

Basic Description

Specifications & Purity99%
Storage TempStore at 2-8°C,Desiccated
Shipped InWet ice
Product Description

PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9) . PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34

In Vitro

PF-06446846 inhibits the secretion of PCSK9 by Huh7 cells with an IC 50 of 0.3 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PF-06446846 (oral gavage; 5-50 mg/kg/day for 14 days) lowers plasma PCSK9 in a dose-dependent manner and lowers total cholesterol levels . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague-Dawley (Crl:CD [SD] rats, 6-8 wk old at initiation of dosing) Dosage: 5, 15, and 50 mg/kg Administration: Oral gavage; daily for 14 days Result: Lowered plasma PCSK9 in a dose-dependent manner and lowered total cholesterol levels.

Form:Solid

IC50& Target:PCSK9

Names and Identifiers

IUPAC Name N-(3-chloropyridin-2-yl)-N-[(3R)-piperidin-3-yl]-4-(triazolo[4,5-b]pyridin-3-yl)benzamide;hydrochloride
INCHI InChI=1S/C22H20ClN7O.ClH/c23-18-5-2-12-25-20(18)29(17-4-1-11-24-14-17)22(31)15-7-9-16(10-8-15)30-21-19(27-28-30)6-3-13-26-21;/h2-3,5-10,12-13,17,24H,1,4,11,14H2;1H/t17-;/m1./s1
InChi Key AQSJYIVIWBIHOU-UNTBIKODSA-N
Canonical SMILES C1CC(CNC1)N(C2=C(C=CC=N2)Cl)C(=O)C3=CC=C(C=C3)N4C5=C(C=CC=N5)N=N4.Cl
PubChem CID 145925649
Molecular Weight 470.4

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Chemical and Physical Properties

SolubilityDMSO : 250 mg/mL (531.52 mM; Need ultrasonic) H2O : 100 mg/mL (212.61 mM; Need ultrasonic)

Safety and Hazards(GHS)

RIDADR NONHforallmodesoftransport

Related Documents

Solution Calculators